GSK-444563/003 (rota-003)

A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus.
Rotavirus Vaccine
444563/003 (rota-003)
Infections, Rotavirus
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2015